In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease.

NPJ Parkinsons Dis · 2023 · PMC10352257 · PMID 37460603

Europe PMC DOI

hedged sentence

0.0754

closest p · 1.5× alpha

0.0754

boldest claim

The sentences

a statistical trendP = 0.0754so close (0.05 < p ≤ 0.1)

Comparison of minzasolmin dose effects demonstrated a statistical trend ( P = 0.0754; unpaired two tailed t test; t = 1.847, df = 28) towards a greater increase in striatal DAT levels in 5 mg/kg minzasolmin -treated ASYN transgenic mice compared to 1 mg/kg.

also in 942 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.